Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: GlobalData
$125.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Dainippon Sumitomo Pharma Co Ltd says alliance with Healios K.K. in regenerative medicine and cell therapy


Monday, 2 Dec 2013 01:00am EST 

Dainippon Sumitomo Pharma Co Ltd:Says signed an agreement on joint development in Japan of iPS cell-derived retinal pigment epithelial cells (RPE cells) for the treatment of age-related macular degeneration and other eye diseases with Healios K.K.Says under the agreement, the company and Healios will launch clinical studies at an early date and seek the manufacturing and marketing approval for indications of age-related macular degeneration and other diseases to make iPS-derived RPE cells available as cell therapy early.Says the company and Healios will co-develop iPS cell-derived RPE cell products in Japan with the fund of maximum 5,200 million yen borne by the company to cover the cost of development.Says Healios will obtain the manufacturing and marketing approval and market RPE cell products.Says the two companies have also signed a joint venture agreement to jointly manufacture and promote the RPE cell products, and the joint venture company is scheduled to be established in Feb. 2014.Says the two companies will hold 50 percent stake respectively in the joint venture capitalized at 50 million yen.Says the two companies have entered into a license agreement under which various technologies and know-hows of Healios including mass culture of the iPS cell-derived RPE cells are licensed to the company. 

Related Company News

Company Quote

1146.0
6.0 +0.53%
11 Jul 2014